Glunektik

Glunektik is a radiopharmaceutical solution for injection that contains fludeoxyglucose (18F) as its diagnostic imaging agent. It is supplied in a sterile liquid form, marketed in the European Union, and prescribed for positron emission tomography (PET) procedures. The compound acts as a glucose analog, allowing visualization of metabolic activity in tissues. Production follows GMP standards and handling requires trained nuclear‑medicine staff safely in clinical settings.

Glunektik is indicated for several PET imaging applications where assessment of cellular glucose metabolism is required.

- Oncology imaging: detection, staging, and monitoring of malignant tumors. - Cardiac viability assessment: evaluation of myocardial perfusion and metabolic activity. - Neurological disorders: investigation of epilepsy, dementia, and movement disorders. - Research studies: quantitative PET imaging in clinical trials. - Inflammatory disease assessment: detection of active inflammation in conditions such as vasculitis. - Therapy response evaluation: measurement of metabolic changes after chemotherapy, radiotherapy, or targeted agents.

Adverse reactions to Glunektik are generally related to the radiopharmaceutical nature of the product and the injection procedure.

Common: - Mild nausea or vomiting that typically resolves without intervention. - Transient flushing or a sensation of warmth at the injection site lasting a few minutes. - Temporary headache occurring shortly after administration. - Low‑grade fatigue reported within the first hour post‑injection.

Serious: - Allergic reactions such as urticaria, rash, or bronchospasm that may require antihistamine or corticosteroid therapy. - Severe hypotension or anaphylaxis presenting with rapid blood pressure drop and respiratory compromise. - Radiation‑induced tissue injury, a rare event that can manifest as localized skin changes or organ dysfunction.

When using Glunektik, several precautions should be observed to ensure patient safety and optimal imaging results.

- Verify patient identity and confirm the indication for PET imaging before administration. - Assess renal function, as impaired clearance may affect tracer distribution. - Ensure adequate hydration to promote renal excretion of the radiotracer. - Observe the patient for at least 15 minutes post‑injection for any acute reactions. - Maintain strict radiation safety protocols for staff and surrounding individuals. - Pregnant or breastfeeding patients should be evaluated carefully, considering potential fetal or infant exposure. - Document the administered activity and time of injection accurately in the patient record.

Glunektik may interact with other agents or conditions that influence glucose metabolism, radiation exposure, or patient stability.

Avoid: - Concurrent administration of other radiopharmaceuticals that emit ionizing radiation, to prevent cumulative dose. - Use of high‑dose glucose‑lowering medications (e.g., insulin) immediately before the scan, which can alter tracer uptake.

Use with caution: - Sedatives or anesthetics that may affect cerebral metabolism and PET image interpretation. - Contrast agents used in CT or MRI performed close in time to the PET scan, which could modify biodistribution. - Patients with uncontrolled diabetes, as hyperglycemia can reduce image quality. - Medications that affect hepatic function, such as certain antifungals, may alter tracer clearance.